Welcome to our dedicated page for Apollomics Warrant news (Ticker: APLMW), a resource for investors and traders seeking the latest updates and insights on Apollomics Warrant stock.
Apollomics Inc is a clinical-stage biopharmaceutical company dedicated to developing oncology therapies that can be combined with other treatments to target the immune system and molecular pathways for cancer treatment. Their lead programs, vebreltinib (APL-101) and uproleselan (APL-106), show promising results in treating various cancers.
Rhea-AI Summary
Apollomics Inc. received a notification from Nasdaq stating that the company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share. The company has 180 days to regain compliance, with the possibility of an additional 180-day period if needed. Failure to regain compliance may lead to delisting from the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
-
Rhea-AI Summary
Apollomics Inc. announced that its Chairman and CEO, Guo-Liang Yu, and President, Sanjeev Redkar, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference. The event will take place on January 18, 2024, at 11:00 a.m. ET. The live webcast will be accessible through B. Riley Securities, and an archived replay will be available on the Apollomics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Apollomics Inc. (Nasdaq: APLM) completes enrollment in Phase 3 bridging study for uproleselan in relapsed or refractory acute myeloid leukemia patients in China
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30%
Tags
Rhea-AI Summary
Apollomics Inc. (APL) announced that Sanjeev Redkar, Ph.D., Co-Founder and President, will present at the 2024 Biotech Showcase on January 8, 2024, to discuss the development of medicines for difficult-to-treat cancers. The presentation will be available via webcast and archived replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30%
Tags
-
Rhea-AI Summary
Apollomics Inc. (Nasdaq: APLM) announced the presentation of vebreltinib efficacy and safety data from the ongoing multi-cohort Phase 2 KUNPENG trial (NCT04258033) and the ongoing global multi-cohort Phase 2 SPARTA trial (NCT03175224) at the 2023 IASLC North America Conference on Lung Cancer (NACLC). Vebreltinib appears efficacious in non-small cell lung cancer (NSCLC) patients with MetExon14 skipping mutation with or without co-occurring MET amplification. The preliminary data from NSCLC patients with MetExon14 skipping mutation from the KUNPENG and SPARTA trials showed the following efficacy and safety results: ORR in patients without co-occurring MET amplification (gene copy number<4, n=76) was 64.5%, with median DOR of 15.9 months and Disease Control Rate (DCR) of 88%. ORR in patients with MET amplification (GCN≥4, n=7) was 85.7%, with DCR of 100%. mDOR was not reached. Treatment-related adverse events of grade 3 or higher were reported in 42.2% of patients, with the most common being edema (13.3%) and ALT increase (7.2%).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
-
Rhea-AI Summary
Apollomics Inc. (APL) to participate in Fireside Chat at H.C. Wainwright 4th Annual Precision Oncology Virtual Conference. Co-Founders Dr. Guo-Liang Yu and Dr. Sanjeev Redkar will discuss the company's oncology drug candidates for difficult-to-treat cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
Rhea-AI Summary
Apollomics Inc. (APLM) presents clinical results for vebreltinib in the treatment of NSCLC with MET exon 14 skipping mutation at 2023 NACLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.36%
Tags
-
Rhea-AI Summary
Apollomics Inc. (Nasdaq: APLM) announces that its partner in China, Avistone Biotechnology Co. Ltd., has received conditional approval from the National Medical Products Administration (NMPA) of China for the commercialization of vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC). Vebreltinib, a potent c-Met inhibitor, offers a potential breakthrough for patients with MET exon 14 skipping NSCLC and other cancers driven by c-Met alterations. The approval is based on compelling clinical data and supports continued development of vebreltinib for the rest of the world. NSCLC accounts for approximately 85% of all lung cancer cases and remains a leading cause of cancer-related deaths worldwide, making this approval a significant achievement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.73%
Tags
-
Rhea-AI Summary
Apollomics Inc. announced the addition of two new cohorts in its Phase 2 SPARTA study, evaluating vebreltinib in patients with non-small cell lung cancer and other solid tumors. The first cohort will evaluate vebreltinib in combination with osimertinib for patients with EGFR-mutated NSCLC, while the second cohort will evaluate vebreltinib monotherapy in solid tumors with high expression of c-MET and HGF. The company aims to address treatment resistance resulting from dysregulations in the HGF/c-MET axis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.57%
Tags
Rhea-AI Summary
Apollomics Inc. announces positive clinical results for vebreltinib in treating GBM with PTPRZ-MET fusion at ESMO 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
FAQ
What is the current stock price of Apollomics Warrant (APLMW)?
The current stock price of Apollomics Warrant (APLMW) is $0.0125 as of December 20, 2024.
What is the market cap of Apollomics Warrant (APLMW)?
The market cap of Apollomics Warrant (APLMW) is approximately 27.9M.
What is Apollomics Inc focused on?
Apollomics Inc focuses on developing oncology therapies that target the immune system and molecular pathways for cancer treatment.
What are Apollomics Inc lead programs?
Apollomics Inc lead programs include vebreltinib (APL-101) and uproleselan (APL-106) which show promising results in treating various cancers.
What is vebreltinib (APL-101) used for?
vebreltinib (APL-101) is a potent, selective c-Met inhibitor used in the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations.
What is uproleselan (APL-106)?
uproleselan (APL-106) is a specific E-Selectin antagonist that could be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
How effective is vebreltinib in treating different tumor types?
Preclinical studies have shown that vebreltinib is effective for a variety of tumor types carrying MET-driver alterations.
What do Phase 2 and 2/3 trials demonstrate about vebreltinib?
Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations.
How can I contact Apollomics Inc for Investor Relations?
For Investor Relations, you can contact Peter Vozzo at ICR Westwicke by email at Peter.Vozzo@westwicke.com or phone at +1-443-213-0505.
How can I contact Apollomics Inc for Media Relations?
For Media Relations, you can contact Sean Leous at ICR Westwicke by email at Sean.Leous@westwicke.com or phone at +1-646-866-4012.
Apollomics Inc. Warrant
Nasdaq:APLMW
APLMW Rankings
APLMW Stock Data
27.88M
109.97M
United States of America